Dr. Reddy's Laboratories has launched Obeda, an oral semaglutide drug for adults with type 2 diabetes in India, as per news reports.
The prescription medicine is to improve glycaemic control alongside diet and exercise. The launch comes shortly after the company introduced generic semaglutide injections in India and Canada as part of its GLP-1 therapy portfolio.
The Central Drugs Standard Control Organisation (CDSCO) cleared the product after reviewing data from a Phase III clinical study conducted in India. The trial included 288 participants diagnosed with type 2 diabetes mellitus.
According to the company, the study showed non-inferior efficacy and a safety profile comparable to the reference oral semaglutide product.
Researchers assessed fasting plasma glucose, post-prandial glucose levels, body weight reduction, and the percentage of participants achieving HbA1c levels below 7% at 12 and 24 weeks.
Dr Reddy’s said Obeda has been developed and manufactured in-house using a recombinant DNA-origin active pharmaceutical ingredient. The medicine will be available in 3 strengths with pricing linked to dosage levels.
The 3 mg tablet has been priced at ₹99 per tablet. The 7 mg variant is priced at ₹135 per tablet, while the 14 mg strength will cost ₹225 per tablet.
The company cited findings from the ICMR-INDIAB study to highlight the scale of diabetes cases in the country. According to the study, India has more than 101 million adults living with diabetes, representing a prevalence rate of 11.4%.
Read More: JSW Motors Secures $826 Million Funding from SBI for Greenfield Manufacturing Facility!
As of May 21, 2026, 11:47 am, Dr Reddy's Laboratories Ltd share price was trading at ₹1,320.10, a 0.14% decrease from the previous closing price.
Obeda has been launched following CDSCO approval based on Phase III clinical data from India. The medicine is intended for adults living with type 2 diabetes.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 21, 2026, 12:26 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
